Skip to main content

Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaq

Oct 22, 2023 10:00 am
Social Author Name
Dr. John Cush
Tweet Content
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN
Show on Archive Page
On
Display in Search Results
On
PDQ
Off